Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Joint Nations Programme on HIV/AIDS

- PMLiVE

WHO updates COVID-19 vaccination strategy to reach unprotected populations

The update raises targets to vaccinate 100% of healthcare workers and 100% of the highest risk populations with primary and booster doses

- PMLiVE

New Omicron sub-variants cause COVID-19 cases to rise in the UK

The latest figures from the Office for National Statistics show infection rates in the UK have more than doubled since the start of June

- PMLiVE

Sanofi Global Health unveils new nonprofit Impact brand

The brand will enable 30 Sanofi medicines to be distributed to 40 low-income countries

- PMLiVE

Gilead Sciences supports Kigali Declaration for neglected tropical diseases

1.7 billion people around the world are affected by tropical diseases, which are prevalent in tropical areas and mostly affect impoverished communities

dengue fever mosquito

Novartis endorses Kigali Declaration by investing $250m for tropical diseases

1.7 billion people suffer from neglected tropical diseases worldwide, and there are 241 million cases of malaria

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Sinovac’s COVID-19 vaccine receives WHO emergency use listing

Vaccine found to be 51% effective in preventing symptomatic disease, meeting the WHO's recommendation of at least 50% efficacy

- PMLiVE

China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine

WHO said decision gives the 'green light' for the vaccine to be rolled out globally

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links